NCT04603365View on ClinicalTrials.gov

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 18, 2021

Primary Completion Date

May 7, 2023

Study Completion Date

May 7, 2023

Conditions
Clear Cell Papillary Renal NeoplasmCollecting Duct CarcinomaHereditary Leiomyomatosis and Renal Cell CarcinomaHereditary Papillary Renal Cell CarcinomaMetastatic Renal Cell CarcinomaMetastatic Unclassified Renal Cell CarcinomaPapillary Renal Cell CarcinomaStage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8Stage IV Renal Cell Cancer AJCC v8Tubulocystic Renal Cell CarcinomaUnresectable Renal Cell Carcinoma
Interventions
DRUG

Pamiparib

Given PO

DRUG

Temozolomide

Given PO

Sponsors

Collaborators (1)

BeiGene
All Listed Sponsors
collaborator

BeiGene

INDUSTRY

collaborator

Driven To Cure

UNKNOWN

lead

Jonsson Comprehensive Cancer Center

OTHER